Entresto (Sacubitril and Valsartan)
Brand Names: Entresto
Methodology & AI Transparency ⓘ
Entresto (Sacubitril and Valsartan) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: As a proprietary angiotensin 2 receptor blocker presentation registered by Aphena Pharma Solutions - Tennessee, LLC, Entresto supplies active moiety Sacubitril and Valsartan (cross-referenced at /meds/sacubitril-and-valsartan) in 6 mg/1 / 6 mg/1 Pellet; 49 mg/1 / 51 mg/1 Tablet, Film Coated (NDC 71610-806, 0078-1231; SPL 2024-03-28).
- 2 Real-world patient consensus: Registered under RxNorm 1656351 and SPL 2024-03-28, pairing Entresto packaging with active ingredient Sacubitril and Valsartan.
- 3 Typical cash cost range: Uninsured 30-day outlay compares $6.98 wholesale mail-order against $34.50 retail pharmacy pricing.
- 4 Top reported side effects / signs: Most commonly reported Entresto (Sacubitril and Valsartan) tolerability events: dizziness (8.3%), cough (6%), orthostatic hypotension (2.5%).
Ask our AI Specialists anything about Entresto (Sacubitril and Valsartan)
Entresto (Sacubitril and Valsartan) Mechanism, CYP450 Pathways & DailyMed Monograph
As a proprietary angiotensin 2 receptor blocker presentation registered by Aphena Pharma Solutions - Tennessee, LLC, Entresto supplies active moiety Sacubitril and Valsartan (cross-referenced at /meds/sacubitril-and-valsartan) in 6 mg/1 / 6 mg/1 Pellet; 49 mg/1 / 51 mg/1 Tablet, Film Coated (NDC 71610-806, 0078-1231; SPL 2024-03-28). Clinical prescribing and dispensing guidelines focus on 1 Indications and usage entresto: is indicated: to reduce the risk of cardiovascular death and hospitalization for heart.
The active constituent inside Entresto—Sacubitril and Valsartan—functions as a targeted angiotensin 2 receptor blocker agent with class-characteristic hepatorenal disposition. While therapeutic target engagement mirrors generic Sacubitril and Valsartan, Entresto (registered by Aphena Pharma Solutions - Tennessee, LLC, SPL 2024-03-28) specifies proprietary packaging (71610-806, 0078-1231) and 6 mg/1 / 6 mg/1 Pellet; 49 mg/1 / 51 mg/1 Tablet, Film Coated quality controls alongside a $11.6248/unit NADAC acquisition baseline.
Clinical clearance of Entresto (Sacubitril and Valsartan) (Angiotensin 2 Receptor Blocker) relies on hepatic enzymatic processing and renal clearance proportional to creatinine clearance (entresto (sacubitril and valsartan)) with a Biphasic clearance with 8–17 hr terminal t½ under Entresto (Sacubitril and Valsartan) maintenance half-life; patients absorbing at Systemic oral bioavailability of roughly 65%–77% following first-pass transit bioavailability typically observe target onset around initial pharmacodynamic onset within 1–2 hrs (peak cmax) for entresto (sacubitril and valsartan).
FDA clinical labeling for Entresto (Sacubitril and Valsartan) restricts administration in documented intolerance or hypersensitivity reaction involving sacubitril and valsartan (angiotensin 2 receptor blocker); concurrent restricted medications flagged in section 4/7 of the entresto (sacubitril and valsartan) dailymed monograph (1656351) across 6 mg/1 / 6 mg/1 Pellet, 49 mg/1 / 51 mg/1 Tablet, Film Coated, 24 mg/1 / 26 mg/1 Tablet, Film Coated, 15 mg/1 / 16 mg/1 Pellet, 97 mg/1 / 103 mg/1 Tablet, Film Coated, with self-reported patient tracking dominated by dizziness (8.3% of reports), headache (6.8% of reports), cough (6% of reports).
Check serum potassium and creatinine periodically if Entresto (Sacubitril and Valsartan) is co-administered with potassium-retaining agents.
Assess baseline hepatic panels and interacting prescriptions when starting Entresto (Sacubitril and Valsartan) (angiotensin 2 receptor blocker).
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Sacubitril and Valsartan (angiotensin 2 receptor blocker)
- Concurrent restricted medications flagged in Section 4/7 of the Entresto (Sacubitril and Valsartan) DailyMed monograph (1656351)
Logged Side-Effect Incidence (16 Reports)
Entresto (Sacubitril and Valsartan) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Entresto (Sacubitril and Valsartan))
Human clinical trial evidence for Entresto (Sacubitril and Valsartan) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Entresto (Sacubitril and Valsartan) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $11.6248/unit (~$348.74/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $6.98 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 16 Anonymous DotMD Community Micro-Logs | $8.03 / mo | View logs ↓ |
Entresto (Sacubitril and Valsartan) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Entresto (Sacubitril and Valsartan) RxNorm Concept ID | 1656351 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $11.6248 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $6.98 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 94.00% Worth It (16 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Entresto (Sacubitril and Valsartan) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Entresto (Sacubitril and Valsartan) (angiotensin 2 receptor blocker) monograph synthesizing RxNorm 1656351, openFDA FAERS signals, and $6.98–$34.50 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Entresto (Sacubitril and Valsartan) community threads and patient logs by age, biological sex, dosage, and treatment duration.